CLAIMS OF THE APPLICATION:

1. (currently amended) A ~~novel~~ crystalline polymorph Form-VI of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (Olanzapine), having an X-ray powder diffraction pattern substantially as depicted in Figure 1.

2. (currently amended) The crystalline polymorph Form-VI of Olanzapine of claim 1, having an X-ray powder diffraction pattern with characteristic d-values (in A°) ~~percentage (in %)~~ substantially as shown in the following table: [[.]]

d-values	Intensity (%)
10.2972	35
8.5646	6
7.6618	22
7.4935	21
7.3691	21
6.6317	25
6.5246	29
6.2320	87
5.7713	7
5.7121	9
5.3042	20
5.2174	6
4.9733	34
4.8335	7
4.7614	5
4.7162	8
4.6284	27
4.4802	13
4.3795	54

4.3163	77
4.4874	100
4.2308	21
4.1297	34
4.0958	34
4.0117	17
3.8275	24
3.7263	13
3.6509	17
3.5311	6
3.3141	29
3.2782	18
3.1207	17
3.0035	5
2.8824	5
2.8099	8
2.8014	6
2.05626	6

3. (canceled)

4. (currently amended) The crystalline polymorph Form-VI of Olanzapine of claim 1, having a differential scanning calorimetry thermogram, which exhibits a characteristic endo peak around 196°C.

5. (currently amended) The crystalline polymorph Form-VI of Olanzapine of claim [[4]] 1, having a differential scanning calorimetry thermogram as depicted in Figure ~~(2)~~.

6. (original) The crystalline polymorph Form-VI of Olanzapine of claim 1, having identified characteristic peaks around 3217 cm^{-1}, 2933 cm^{-1}, 1592 cm^{-1}, 1561 cm^{-1}, 1468 cm^{-1}, 1369 cm^{-1}, 1218 cm^{-1}, 1143 cm^{-1}, 1007 cm^{-1}, 964 cm^{-1}, 751 cm^{-1} and 674 cm^{-1} in the Infra red Spectrum.

7. (currently amended) The crystalline polymorph Form-VI of Olanzapine of claim ~~6~~ 1, having an Infrared spectrum as depicted in Figure ~~(3)~~.

8. (currently amended) A process for the preparation of ~~novel~~ a crystalline polymorph Form-VI of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (Olanzapine), having an X-ray powder diffraction pattern substantially as depicted in Figure 1, which comprises;

(i) stirring polymorph Form-I of Olanzapine in a C_1-C_6 alkanol at a temperature of 0 to 40°C for 30 minutes to 10 hours;

(ii) isolating the obtained solid form step (i) by conventional methods; and

(iii) drying the compound of step (ii) at a temperature of 40 to 100°C to afford the desired crystalline polymorph Form-VI of Olanzapine.

9. (currently amended) The process as claimed in claim 8, ~~of step (i),~~ wherein ~~the~~ said ~~alcohol~~ C_1-C_6 alkanol in step (i) is *n*-butanol or *tert*-butanol.

10. (currently amended) A composition comprising ~~novel~~ crystalline Form-VI of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine according to ~~anyone~~ any one of claims ~~1~~ 1, 2 and ~~to~~ 4-7 and a pharmaceutically acceptable carrier, diluent, excipient, additive, filler, lubricant, binder, stabilizer, solvent or solvate.

11. (currently amended) The composition according to claim 10, in the form of a tablet, capsule, lozenge, powder, syrup, solution, suspension, ointment, or dragée ~~dragee~~.

12. (canceled)

13. (currently amended) A method for treating a disorder of the central nervous system comprising administering an effective amount of crystalline Form-VI of 2-methyl-4-1(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine according to ~~anyone~~ any one of claim~~s~~ 1, 2 and 4-7 and a pharmaceutically acceptable carrier, diluent, excipient, additive, filler, lubricant, binder, stabilizer, solvent or solvate to a patient in need thereof.

14. (currently amended) A composition ~~medicine~~ for the treatment of a disorder of the central nervous system comprising an effective amount of crystalline Form-VI of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine according to ~~anyone~~ any one of claim~~s~~ 1, 2 and 4-7.

15. (canceled)